Physician profile
Darrin M Ray
NPI 1679785778
$659.19
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $490 · 2020: $141 · 2021: $12.26 · 2023: $16.25.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $16.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $16.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $208.67 | 2019-2020 | |
| Novo Nordisk INC | $145.88 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $91.74 | 2019 | |
| Avanir Pharmaceuticals, INC. | $39.97 | 2020-2021 | |
| Lilly USA, LLC | $32.54 | 2019 | |
| Astellas Pharma US INC | $25.29 | 2019-2020 | |
| Glaxosmithkline, LLC. | $24.24 | 2020 | |
| Alkermes, INC. | $17.72 | 2019 | |
| Amgen INC. | $17.07 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $16.25 | 2023 | Nuedexta |
| Janssen Pharmaceuticals, INC | $15.33 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.31 | 2020 | |
| Neurocrine Biosciences, INC. | $11.18 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Darrin Ray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.